Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration

INTRODUCTION: Based on the advances in the treatment of multiple sclerosis (MS), currently available disease-modifying treatments (DMT) have positively influenced the disease course of MS. However, the efficacy of DMT is highly variable and increasing treatment efficacy comes with a more severe risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Willekens, Barbara, Presas-Rodríguez, Silvia, Mansilla, MJ, Derdelinckx, Judith, Lee, Wai-Ping, Nijs, Griet, De Laere, Maxime, Wens, Inez, Cras, Patrick, Parizel, Paul, Van Hecke, Wim, Ribbens, Annemie, Billiet, Thibo, Adams, Geert, Couttenye, Marie-Madeleine, Navarro-Barriuso, Juan, Teniente-Serra, Aina, Quirant-Sánchez, Bibiana, Lopez-Diaz de Cerio, Ascensión, Inogés, Susana, Prosper, Felipe, Kip, Anke, Verheij, Herman, Gross, Catharina C, Wiendl, Heinz, Van Ham, Marieke (SM), Ten Brinke, Anja, Barriocanal, Ana Maria, Massuet-Vilamajó, Anna, Hens, Niel, Berneman, Zwi, Martínez-Cáceres, Eva, Cools, Nathalie, Ramo-Tello, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738722/
https://www.ncbi.nlm.nih.gov/pubmed/31501122
http://dx.doi.org/10.1136/bmjopen-2019-030309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738722/
https://www.ncbi.nlm.nih.gov/pubmed/31501122
http://dx.doi.org/10.1136/bmjopen-2019-030309

Ejemplares similares